Social engagement
Social engagement: 436 social following, 1 post in the last 12 months — below the industry typical range.
Investor mix
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Other / undisclosed | 1 | 100% |
Developer of therapies focused on neurofibromatosis type 2 genetic defects
Social engagement: 436 social following, 1 post in the last 12 months — below the industry typical range.
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Other / undisclosed | 1 | 100% |